Ronald Lloyd Announced as New President and CEO of Aziyo Biologics
Seasoned leader brings a wealth of experience in commercial and business development
SILVER SPRING, Md.–(BUSINESS WIRE)–Aziyo Biologics, Inc., a fully integrated regenerative medicine company, announced today the appointment of Ronald (Ron) Lloyd as President and Chief Executive Officer of the company. Mr. Lloyd will be based in the Silver Spring, Maryland office with responsibility for all aspects of the rapidly growing Aziyo organization. He will also become a member of the Company’s Board of Directors.
“We are thrilled to add Ron to the Aziyo leadership team,” said Kevin Rakin, Chairman of the Aziyo Board of Directors. “Ron’s deep experience in building regenerative medicine businesses through both organic and transactional means is a perfect fit for our company’s aggressive growth targets.”
Mr. Lloyd most recently served as Executive Vice President and President of Hospital Therapies for Mallinckrodt Pharmaceuticals where he created an integrated hospital organization with revenues exceeding $1 billion. While at Mallinckrodt he also led numerous business development transactions in areas that parallel many of Aziyo’s commercial interests, including licensure of a late-stage program for the treatment of cardiac arrest and the acquisition of Stratatech Corp., a privately held company focused on developing regenerative skin tissue.
“From the moment I was introduced to the Aziyo opportunity, I knew it was a perfect fit for me. Regenerative medicine, commercial strategy and business development are all passions of mine,” commented Mr. Lloyd, “I look forward to leading this talented, resource-rich organization to drive commercial success in the regenerative medicine space.”
Prior to Mallinckrodt, Mr. Lloyd was with Baxter Healthcare where he held the positions of President of Immunology, General Manager, BioScience and Vice President, Global Marketing for the BioScience Division. His tenure at Baxter included a leadership role in developing and implementing strategies to build a regenerative medicine business. Mr. Lloyd holds a Master of Science in Industrial Administration from Carnegie Mellon University and a Bachelor of Arts in Management Science from Westminster College, where he was a two-time basketball academic all-American.
About Aziyo Biologics, Inc.
Aziyo Biologics is a fully integrated, commercially oriented regenerative medicine company. Since its founding in 2015 the Company has expanded through acquisitions and strategic partnerships, creating a high growth commercial entity. Its proprietary products are used in orthopedic, cardiovascular and other medical specialties.
Aziyo Biologics, Inc.
Erica Elchin, 510-730-7896
Could HighCape be the right partner for your growing business?
Contact us for more information.
452 5th Ave, 21st Floor
New York, NY 10018